-
1
-
-
11444267243
-
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD
-
Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
-
(2005)
Neurology
, vol.64
, pp. 94-101
-
-
Bayer, A.J.1
Bullock, R.2
Jones, R.W.3
Wilkinson, D.4
Paterson, K.R.5
Jenkins, L.6
-
2
-
-
1042265187
-
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
-
Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
-
(2004)
Brain Pathol
, vol.14
, pp. 11-20
-
-
Ferrer, I.1
Boada Rovira, M.2
Sanchez Guerra, M.L.3
Rey, M.J.4
Costa-Jussa, F.5
-
3
-
-
20944448555
-
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
-
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562
-
(2005)
Neurology
, vol.64
, pp. 1553-1562
-
-
Gilman, S.1
Koller, M.2
Black, R.S.3
Jenkins, L.4
Griffith, S.G.5
Fox, N.C.6
-
4
-
-
0038100154
-
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease
-
Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554
-
(2003)
Neuron
, vol.38
, pp. 547-554
-
-
Hock, C.1
Konietzko, U.2
Streffer, J.R.3
Tracy, J.4
Signorell, A.5
Muller-Tillmanns, B.6
-
5
-
-
47149112621
-
Long term effect of Abeta42 immunization in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase i trial
-
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long term effect of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223
-
(2008)
Lancet
, vol.372
, pp. 216-223
-
-
Holmes, C.1
Boche, D.2
Wilkinson, D.3
Yadegarfar, G.4
Hopkins, V.5
Bayer, A.6
-
6
-
-
76849091134
-
Can Alzheimer disease be prevented by amyloid-beta immunotherapy?
-
Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6: 108-119
-
(2010)
Nat Rev Neurol
, vol.6
, pp. 108-119
-
-
Lemere, C.A.1
Masliah, E.2
-
7
-
-
19944429065
-
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
-
Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131
-
(2005)
Neurology
, vol.64
, pp. 129-131
-
-
Masliah, E.1
Hansen, L.2
Adame, A.3
Crews, L.4
Bard, F.5
Lee, C.6
-
8
-
-
33750586141
-
Abeta species removal after Abeta42 immunization
-
Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta Species Removal After Abeta42 Immunization. J Neuropathol Exp Neurol 2006; 65: 1040-1048
-
(2006)
J Neuropathol Exp Neurol
, vol.65
, pp. 1040-1048
-
-
Nicoll, J.A.1
Barton, E.2
Boche, D.3
Neal, J.W.4
Ferrer, I.5
Thompson, P.6
-
9
-
-
0037393454
-
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report
-
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452
-
(2003)
Nat Med
, vol.9
, pp. 448-452
-
-
Nicoll, J.A.1
Wilkinson, D.2
Holmes, C.3
Steart, P.4
Markham, H.5
Weller, R.O.6
-
10
-
-
33748767945
-
Amyloid-beta peptide remnants in AN-1792-immu-nized Alzheimer's disease patients: A biochemical analysis
-
Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-beta peptide remnants in AN-1792-immu-nized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048-1063
-
(2006)
Am J Pathol
, vol.169
, pp. 1048-1063
-
-
Patton, R.L.1
Kalback, W.M.2
Esh, C.L.3
Kokjohn, T.A.4
Van Vickle, G.D.5
Luehrs, D.C.6
-
11
-
-
77949300796
-
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study
-
Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372
-
(2010)
Lancet Neurol
, vol.9
, pp. 363-372
-
-
Rinne, J.O.1
Brooks, D.J.2
Rossor, M.N.3
Fox, N.C.4
Bullock, R.5
Klunk, W.E.6
-
12
-
-
0033536163
-
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
-
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177
-
(1999)
Nature
, vol.400
, pp. 173-177
-
-
Schenk, D.1
Barbour, R.2
Dunn, W.3
Gordon, G.4
Grajeda, H.5
Guido, T.6
-
13
-
-
64549152492
-
Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders
-
Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6: 144-151
-
(2009)
Curr Alzheimer Res
, vol.6
, pp. 144-151
-
-
Vellas, B.1
Black, R.2
Thal, L.J.3
Fox, N.C.4
Daniels, M.5
McLennan, G.6
|